IBDEI170 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19167,1,3,0)
 ;;=3^Dysphagia following oth nontraumatic intracranial hemorrhage
 ;;^UTILITY(U,$J,358.3,19167,1,4,0)
 ;;=4^I69.291
 ;;^UTILITY(U,$J,358.3,19167,2)
 ;;=^5007485
 ;;^UTILITY(U,$J,358.3,19168,0)
 ;;=I69.091^^93^989^19
 ;;^UTILITY(U,$J,358.3,19168,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19168,1,3,0)
 ;;=3^Dysphagia following nontraumatic subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,19168,1,4,0)
 ;;=4^I69.091
 ;;^UTILITY(U,$J,358.3,19168,2)
 ;;=^5007421
 ;;^UTILITY(U,$J,358.3,19169,0)
 ;;=I69.891^^93^989^21
 ;;^UTILITY(U,$J,358.3,19169,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19169,1,3,0)
 ;;=3^Dysphagia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,19169,1,4,0)
 ;;=4^I69.891
 ;;^UTILITY(U,$J,358.3,19169,2)
 ;;=^5007547
 ;;^UTILITY(U,$J,358.3,19170,0)
 ;;=I69.321^^93^989^22
 ;;^UTILITY(U,$J,358.3,19170,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19170,1,3,0)
 ;;=3^Dysphasia following cerebral infarction
 ;;^UTILITY(U,$J,358.3,19170,1,4,0)
 ;;=4^I69.321
 ;;^UTILITY(U,$J,358.3,19170,2)
 ;;=^5007492
 ;;^UTILITY(U,$J,358.3,19171,0)
 ;;=I69.121^^93^989^23
 ;;^UTILITY(U,$J,358.3,19171,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19171,1,3,0)
 ;;=3^Dysphasia following nontraumatic intracerebral hemorrhage
 ;;^UTILITY(U,$J,358.3,19171,1,4,0)
 ;;=4^I69.121
 ;;^UTILITY(U,$J,358.3,19171,2)
 ;;=^5007428
 ;;^UTILITY(U,$J,358.3,19172,0)
 ;;=I69.021^^93^989^24
 ;;^UTILITY(U,$J,358.3,19172,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19172,1,3,0)
 ;;=3^Dysphasia following nontraumatic subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,19172,1,4,0)
 ;;=4^I69.021
 ;;^UTILITY(U,$J,358.3,19172,2)
 ;;=^5007396
 ;;^UTILITY(U,$J,358.3,19173,0)
 ;;=I69.821^^93^989^26
 ;;^UTILITY(U,$J,358.3,19173,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19173,1,3,0)
 ;;=3^Dysphasia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,19173,1,4,0)
 ;;=4^I69.821
 ;;^UTILITY(U,$J,358.3,19173,2)
 ;;=^5007523
 ;;^UTILITY(U,$J,358.3,19174,0)
 ;;=I69.221^^93^989^25
 ;;^UTILITY(U,$J,358.3,19174,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19174,1,3,0)
 ;;=3^Dysphasia following oth nontraumatic intracranial hemorrhage
 ;;^UTILITY(U,$J,358.3,19174,1,4,0)
 ;;=4^I69.221
 ;;^UTILITY(U,$J,358.3,19174,2)
 ;;=^5007460
 ;;^UTILITY(U,$J,358.3,19175,0)
 ;;=G11.1^^93^989^27
 ;;^UTILITY(U,$J,358.3,19175,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19175,1,3,0)
 ;;=3^Early-onset cerebellar ataxia
 ;;^UTILITY(U,$J,358.3,19175,1,4,0)
 ;;=4^G11.1
 ;;^UTILITY(U,$J,358.3,19175,2)
 ;;=^5003753
 ;;^UTILITY(U,$J,358.3,19176,0)
 ;;=I69.392^^93^989^28
 ;;^UTILITY(U,$J,358.3,19176,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19176,1,3,0)
 ;;=3^Facial weakness following cerebral infarction
 ;;^UTILITY(U,$J,358.3,19176,1,4,0)
 ;;=4^I69.392
 ;;^UTILITY(U,$J,358.3,19176,2)
 ;;=^5007517
 ;;^UTILITY(U,$J,358.3,19177,0)
 ;;=I69.192^^93^989^29
 ;;^UTILITY(U,$J,358.3,19177,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19177,1,3,0)
 ;;=3^Facial weakness following nontraumatic intcrbl hemorrhage
 ;;^UTILITY(U,$J,358.3,19177,1,4,0)
 ;;=4^I69.192
 ;;^UTILITY(U,$J,358.3,19177,2)
 ;;=^5007454
 ;;^UTILITY(U,$J,358.3,19178,0)
 ;;=I69.292^^93^989^31
 ;;^UTILITY(U,$J,358.3,19178,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19178,1,3,0)
 ;;=3^Facial weakness following oth nontraumatic intcrn hemorrhage
 ;;^UTILITY(U,$J,358.3,19178,1,4,0)
 ;;=4^I69.292
